全身麻醉使用逆轉神經肌肉阻斷劑 Sugammadex 的成本效益分析

Cost-benefit analysis of the muscule relaxant antagonist sugammadex in general anesthesia

在醫療機構經營困苦的年代中，利用理論深入剖析全身麻醉成本，為病患、醫護人員、醫院及社會創造四贏的局面。藉由方法論與成本效益策略，建構全身麻醉成本計算模型。收集44,328 人，使用有2,951 人，無重插管。無使用41,377 人，重插管0.045%，重插管後轉入加護病房100%、重插管後死亡率10.53%。入住加護病房NT11,334 元/ 人、生產力損失NT1,570.2 元/ 人/ 天。且社會成本增加NT2,902.3 元/ 人。總結而言，具有降低住院天數、減少醫療資源浪費與提升醫療品質等優點。

The residual effect of neuromuscular blocking agents after surgery delays the recovery timeand increases mortality risk. In this project, we performed a cost-benefit analysis of sugammadexin perioperative care. The incidence of reintubation complications after general anesthesia| wasanalyzed for determining the cost-effectiveness of sugammadex in terms of self-funded medicalincome, postoperative patient satisfaction, and medical resources from the hospital perspectivein decreasing the possibility of postoperative re-intubation. In total, we included 44,328 patients|of them, 2,951 we in the sugammadex group and 41,377 were in the control group, and theirincidence rates of reintubation 0% and 0.045%, respectively. The mortality rate of the reintubatedpatients was 10.53%, and the net benefit value was 1,656,903.60 (Yiben ratio = 1.08). For there-intubated patients in the intensive care unit, the average per-patient cost was 11,334, andthe per-person per-day productivity loss was 1,570.2. Nevertheless, sugammadex use reducedthe per-person social cost by 2,902.3. Taken together, sugammadex use not only increasespatient satisfaction. but also reduces complications and length of hospital stays, thereby improvingthe overall medical care quality.